2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer Review uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

abstract

  • In patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

publication date

  • October 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3675703

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.34.2774

PubMed ID

  • 21900105

Additional Document Info

start page

  • 3825

end page

  • 31

volume

  • 29

number

  • 28